CRISPR Therapeutics to Present Zugo-cel Clinical Data at ASH Meeting
What happened
CRISPR Therapeutics announced that it will present clinical data on zugocabtagene geleucel, an investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy. The therapy is being studied in patients with relapsed or refractory large B-cell lymphoma. The presentation, which details dose-dependent efficacy, is scheduled for the 68th American Society of Hematology Annual Meeting on December 13, 2026.
From manilatimes.net
Why it matters
The presentation covers the efficacy of zugocabtagene geleucel in highly refractory large B-cell lymphoma. As a gene-edited CAR T cell therapy, positive clinical outcomes could influence the commercial viability and market adoption of this type of advanced immunotherapy.
From manilatimes.net
Who's involved
- CRISPR TherapeuticsIs presenting clinical data on its investigational allogeneic CAR T cell therapy.
- American Society of HematologyIs hosting the meeting where the clinical data will be presented.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- New clinical data may advance FDA review of CRISPR's gene therapyPositive clinical data may advance FDA review of CRISPR's gene therapyLikely
- How could CRISPR Therapeutics' new clinical data affect Eli Lilly and Company?CRISPR data may intensify competition for high-growth biotech market sharePossible
- New clinical data may boost zugo-cel's chance in EuropeNew clinical data may boost zugo-cel's chance in EuropePossible
- Intellia Therapeutics may face competitive pressure from CRISPR's new dataIntellia Therapeutics may face increased competitive pressure from CRISPR's new gene-edited therapy dataPossible
- Ark Invest's stake in CRISPR Therapeutics may benefit from new dataArk Invest's portfolio holding in CRISPR Therapeutics may gain valuePossible
Keep exploring
The entities involved
-
CRISPR Therapeutics
company in Basel, Switzerland
-
American Society of Hematology
organization
Related events
- CRISPR Therapeutics, Eli Lilly, and Johnson & Johnson are noted as major holdings in health care ETFs.
- CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.
- CRISPR Therapeutics formed a strategic partnership with Vertex Pharmaceuticals.
- Orna Therapeutics was acquired by Eli Lilly and Company, a development within the RNA therapeutics sector.